Paragraph 23 F1

For medicinal products included on the list referred to—

(a)

in the case of a F2UKMA(NI) or a UKMA(UK)(Category 2), in Article 23 of Regulation (EC) No 726/2004, the symbol and statement “▼ This medicinal product is subject to additional monitoring”, or

(b)

in the case of a F3UKMA(GB) or a UKMA(UK)(Category 1), in regulation 202A, the symbol and statement “▼ This medicinal product is subject to additional monitoring”.

Annotations

Textual amendments

F1: Sch. 8 para. 23 substituted (31.12.2020) by S.I. 2019/775, reg. 50(8) (as substituted by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 38(g))
F2: Words in Sch. 8 para. 23(a) substituted (1.1.2025) by The Human Medicines (Amendments relating to the Windsor Framework) Regulations 2024 (S.I. 2024/832), regs. 1(1), 137(b)(i)
F3: Words in Sch. 8 para. 23(b) substituted (1.1.2025) by The Human Medicines (Amendments relating to the Windsor Framework) Regulations 2024 (S.I. 2024/832), regs. 1(1), 137(b)(ii)